SCHEMBL1199541

SCHEMBL1199541

O=Cc1sc(-c2cccc(C(F)(F)F)c2)nc1COC1CCCCO1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.40
PPARA Q07869 2/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
MAPT P10636 1/20 0.39
GRIN1 Q05586 6/20 0.39
GRIN2B Q13224 6/20 0.39
ALDH1A1 P00352 4/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALPL P05186 1/20 0.36
ALPI P09923 1/20 0.36
KDM4C Q9H3R0 1/20 0.35
PPARD Q03181 1/20 0.35
TSHR P16473 1/20 0.34
POLB P06746 1/20 0.34
ADORA1 P30542 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4811119 0.88 KDM4E (0.35) PPARGPPARAMEN1KMT2AMAPT
SCHEMBL1199248 0.87 GRIN1 (0.38) PPARGPPARAMEN1KMT2AMAPT
SCHEMBL12876144 0.87 RAB9A (0.38) PPARGPPARAMAPTALDH1A1SMN1; SMN2
SCHEMBL1198600 0.87 GRIN1 (0.38) PPARGPPARAMEN1KMT2AMAPT
SCHEMBL1198888 0.86 GRIN1 (0.37) PPARGPPARAMEN1KMT2AMAPT
SCHEMBL1197624 0.85 MEN1 (0.41) PPARGPPARAMEN1KMT2AMAPT
SCHEMBL1199130 0.85 MAPT (0.39) PPARGPPARAMEN1KMT2AMAPT
SCHEMBL1198819 0.79 ALDH1A1 (0.44) PPARGPPARAMEN1KMT2AMAPT
SCHEMBL1199086 0.78 PPARG (0.36) PPARGPPARAKDM4C
SCHEMBL2431523 0.75 GRIN1 (0.42) MAPTGRIN1GRIN2BKDM4CTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A PPARG 139/4885PPARA 517/4885MEN1 2661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.